Basisstatistiken
| LEI | 254900IXI5NI8C9OQE24 |
| CIK | 1468748 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kodiak Sciences Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2026 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2026 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Palo Alto, Calif., May 7, 2026 - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts a |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| April 23, 2026 |
TO OUR KODIAK STOCKHOLDERS, EMPLOYEES AND PARTNERS When I wrote to you last year, I asked you to look at Kodiak with fresh eyes— to see, beneath the market turbulence, a company grounded in science with the potential to build something enduring. |
|
| April 22, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 31, 2026 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results PALO ALTO, Calif., March 31, 2026 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topli |
|
| March 31, 2026 |
Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Exhibit 107 Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity(1) Common Stock Other 2,470,338 $21.57 $53,285,190.66 0.00013810 $7,358.68 Total Offering Amounts |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| March 31, 2026 |
SUBSIDIARIES OF KODIAK SCIENCES INC. Exhibit 21.1 SUBSIDIARIES OF KODIAK SCIENCES INC. The following is a list of subsidiaries of Kodiak Sciences Inc. at December 31, 2025. Subsidiary Name Jurisdiction of Incorporation or Formation Kodiak Sciences GmbH Switzerland Kodiak Sciences Valais GmbH Switzerland Kodiak Sciences Financing Corporation Delaware |
|
| March 31, 2026 |
EXPLANATORY NOTE SIGNATURES POWER OF ATTORNEY As filed with the U.S. Securities and Exchange Commission on March 31, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KODIAK SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27-0476525 (I.R.S |
|
| March 27, 2026 |
EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham • Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 18, 2025 |
EX-1.1 Exhibit 1.1 KODIAK SCIENCES INC. 6,956,522 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement December 16, 2025 J.P. MORGAN SECURITIES LLC JEFFERIES LLC EVERCORE GROUP L.L.C. UBS SECURITIES LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 270 Park Avenue New York, NY 810017 c/o Jefferies LLC 520 Madison Ave |
|
| December 17, 2025 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271946 Prospectus supplement (To prospectus dated June 2, 2023) 6,956,522 Shares Common stock We are offering 6,956,522 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “KOD.” On December 12, 2025, the last reported sale price for our common stock on The Nasdaq Global Ma |
|
| December 15, 2025 |
Subject to completion, dated December 15, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 13, 2025 |
Press Release published by Kodiak Sciences Inc. dated November 13, 2025 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results Palo Alto, Calif., November 13, 2025 - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling clinical data, ac |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| August 13, 2025 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results Palo Alto, Calif., August 13, 2025 - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2025 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results Palo Alto, CA — May 14, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. “In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at a |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| April 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 22, 2025 |
TO OUR KODIAK STOCKHOLDERS, EMPLOYEES, AND PARTNERS Since Kodiak’s founding in 2009, we have been unwavering in our commitment to develop important new medicines for the treatment and prevention of vision loss. |
|
| March 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KODIAK SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27-0476525 (I.R.S |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 27, 2025 |
Kodiak Sciences Inc. Insider Trading Policy Exhibit 19.1 KODIAK SCIENCES INC. INSIDER TRADING POLICY 1. POLICY OVERVIEW The purpose of this Insider Trading Policy (“Policy”) is to ensure that all directors, officers, employees, consultants, contractors and agents (e.g. auditors, consultants, board observers and attorneys) of Kodiak Sciences Inc. and its subsidiaries (“Company”) trade and transact the Company’s securities lawfully and ethica |
|
| March 27, 2025 |
Exhibit 21.1 SUBSIDIARIES OF KODIAK SCIENCES INC. The following is a list of subsidiaries of Kodiak Sciences Inc. at December 31, 2024. Certain subsidiaries have been omitted as they are not significant in the aggregate. Subsidiary Name Jurisdiction of Incorporation or Formation Kodiak Sciences GmbH Switzerland Kodiak Sciences Valais GmbH Switzerland |
|
| March 27, 2025 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Palo Alto, CA — March 27, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlr |
|
| March 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other(2) 2,109,076(3) $3.12(2) $6,580,318 0.00015310 $1,008 Total Offering Amount |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 14, 2024 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results Palo Alto, CA — November 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. “In the third quarter we hosted an Investor R&D Day in New York,” said Victor Perlroth, M.D., Chief Executive Officer of K |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 14, 2024 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results Palo Alto, CA — August 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. “Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress,” said Victor Perlroth, M |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2024 |
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results Palo Alto, CA — May 15, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. “We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 23, 2024 |
THE OPHTHALMOLOGY MEDICINES COMPANY 2024 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT 2023 ANNUAL REPORTKODIAK SCIENCES INC. |
|
| April 23, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 28, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97.1 Kodiak Sciences Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Kodiak Sciences Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverabl |
|
| March 28, 2024 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points • New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting • Phase 1b study of KSI-1 |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other(2) 2,100,344(3) $5.75(2) $12,076,978 0.00014760 $1,783 Total Offering Amo |
|
| March 28, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2024 As filed with the U.S. Securities and Exchange Commission on March 28, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KODIAK SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 27-0476525 (State or other jurisdiction of incorporation or organization) (I. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 14, 2024 |
KOD / Kodiak Sciences Inc. / PERLROTH VICTOR - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 26, 2024 |
KOD / Kodiak Sciences Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us50015m1099012624.txt us50015m1099012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) KODIAK SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 50015M109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 14, 2023 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA — November 14, 2023 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. “We have three retinal disease prospects in our pipeline: two molecules built with our antibody biopolymer conjugate platf |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 14, 2023 |
Exhibit 99.1 Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA — August 14, 2023 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the q |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 31, 2023 |
KODIAK SCIENCS INC. 1200 Page Mill Road Palo Alto, California 94304 CORRESP KODIAK SCIENCS INC. 1200 Page Mill Road Palo Alto, California 94304 May 31, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama RE: Kodiak Sciences Inc. Registration Statement on Form S-3 File No. 333-271946 Acceleration Request Requested Date: Friday, June 2, 2023 Requested Time: |
|
| May 22, 2023 |
United States securities and exchange commission logo May 19, 2023 John Borgeson Chief Financial Officer Kodiak Sciences Inc. |
|
| May 15, 2023 |
Form of Indenture, between the Company and one or more trustees to be named EX-4.4 Exhibit 4.4 KODIAK SCIENCES INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate EX-4.6 Exhibit 4.6 KODIAK SCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing un |
|
| May 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) KODIAK SCIENCES INC. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| May 15, 2023 |
Power of Attorney (included on signature page) S-3 As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 15, 2023 |
Exhibit 99.1 Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA — May 15, 2023 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quart |
|
| May 15, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate EX-4.8 Exhibit 4.8 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Kodiak Sciences Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exis |
|
| May 15, 2023 |
KODIAK SCIENCS INC. 1200 Page Mill Road Palo Alto, California 94304 KODIAK SCIENCS INC. 1200 Page Mill Road Palo Alto, California 94304 May 15, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius RE: Kodiak Sciences Inc. Registration Statement on Form S-3 File No. 333-271043 Acceleration Request Requested Date: Wednesday, May 17, 2023 Requested Time: 4:00 p.m. |
|
| May 15, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate EX-4.7 Exhibit 4.7 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exis |
|
| April 25, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 25, 2023 |
THE OPHTHALMOLOGY MEDICINES COMPANY 2023 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT 2022 ANNUAL REPORT Illustration of Kodiak’s ABC Platform in action in the retina. |
|
| April 5, 2023 |
United States securities and exchange commission logo April 5, 2023 D. Victor Perlroth, M.D. Chairman and Chief Executive Officer Kodiak Sciences Inc. 1200 Page Mill Road Palo Alto, California 94304 Re: Kodiak Sciences Inc. Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271043 Dear D. Victor Perlroth: This is to advise you that we have not reviewed and will not review your re |
|
| March 31, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kodiak Sciences Inc. |
|
| March 31, 2023 |
Power of Attorney (included on signature page). S-3 Table of Contents As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other(2) 2,093,354(3) $4.95 (2) $10,362,102.30 0.0001102 $1,141.90 Total Offering |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 28, 2023 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Palo Alto, CA — March 28, 2023 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resu |
|
| March 28, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KODIAK SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27-0476525 (I.R.S |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| February 14, 2023 |
KOD / Kodiak Sciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 kod13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) KODIAK SCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule purs |
|
| February 14, 2023 |
KOD / Kodiak Sciences Inc. / PERLROTH VICTOR - SC 13G/A Passive Investment SC 13G/A 1 d432730dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 9, 2023 |
KOD / Kodiak Sciences Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01254-kodiaksciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Kodiak Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 50015M109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desig |
|
| February 3, 2023 |
KOD / Kodiak Sciences Inc. / BlackRock Inc. Passive Investment us50015m1099020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) KODIAK SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 50015M109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 9, 2022 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA ? November 9, 2022 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the q |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2022 |
Exhibit 99.1 Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA ? August 9, 2022 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the qu |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 6, 2022 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 18, 2022 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 10, 2022 |
Exhibit 99.1 Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA ? May 10, 2022 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quart |
|
| May 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KODIAK SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 27-0476525 (I.R.S. |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Kodiak Sciences Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other(2) 2,073,050(3) $6.22 (2) $12,894,371.00 0.0000927 $1,195.31 Total Offering |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| April 28, 2022 |
DEF 14A 1 d161557ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 10, 2022 |
KOD / Kodiak Sciences Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Kodiak Sciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50015M109 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| March 10, 2022 |
KOD / Kodiak Sciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) February 28, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| March 9, 2022 |
KOD / Kodiak Sciences Inc. / BlackRock Inc. Passive Investment us50015m1099030922.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) KODIAK SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 50015M109 - (CUSIP Number) February 28, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| March 1, 2022 |
Outside Director Compensation Policy Exhibit 10.16 KODIAK SCIENCES INC. OUTSIDE DIRECTOR COMPENSATION POLICY Amended and Restated by the Board of Directors: September 29, 2021 Kodiak Sciences Inc. (the ?Company?) believes that granting equity and cash compensation to members of its Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract, retain, and reward Directors who are |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 1, 2022 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights Palo Alto, CA ? March 1, 2022 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resul |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| February 23, 2022 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
KOD / Kodiak Sciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| February 14, 2022 |
KOD / Kodiak Sciences Inc. / PERLROTH VICTOR - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 10, 2022 |
KOD / Kodiak Sciences Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Kodiak Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 50015M109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 4, 2022 |
KOD / Kodiak Sciences Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Kodiak Sciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 3, 2022 |
KOD / Kodiak Sciences Inc. / BlackRock Inc. Passive Investment us50015m1099020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) KODIAK SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 50015M109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 31, 2022 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 15, 2021 |
As filed with the Securities and Exchange Commission on December 15, 2021 Registration No. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2021 |
2021 Long-Term Performance Incentive Plan Exhibit 10.1 Kodiak Sciences Inc. 2021 Long-Term Performance Incentive Plan 1. General. (a) Purpose. As part of its employee compensation program, Kodiak Sciences Inc. (the ?Company?) has adopted this 2021 Long-Term Performance Incentive Plan (the ?Plan?), effective as of August 12, 2021 (the ?Effective Date?), subject to Section 2 below. The purpose of the Plan is to help attract and retain key e |
|
| November 9, 2021 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA ? November 9, 2021 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the t |
|
| October 15, 2021 |
Exhibit 99.1 Summary of the LTPIP Overview Below is an overview of the LTPIP, which is intended as a summary only and is qualified in its entirety by the full text of the LTPIP attached to this proxy statement as Appendix 1. Plan Terms Details Eligible Employees Employees at Grade Level 10 and above who elect to participate in the Plan and agree to forgo a portion of their annual long-term incenti |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defini |
|
| October 1, 2021 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| September 1, 2021 |
Press Release issued by Kodiak Sciences Inc. dated September 1, 2021 Exhibit 99.1 Kodiak Sciences Announces New Long-Term Performance Incentive Plan Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share Palo Alto, CA ? September 1, 2021 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t |
|
| September 1, 2021 |
Kodiak Sciences Announces New Long-Term Performance Incentive Plan Exhibit 99.1 Kodiak Sciences Announces New Long-Term Performance Incentive Plan Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share Palo Alto, CA ? September 1, 2021 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2021 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2021 KODIAK SCIENCES INC. |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| August 9, 2021 |
Exhibit 99.1 Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA ? August 9, 2021 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the se |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2021 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| July 26, 2021 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| July 23, 2021 |
Letter Agreement, dated July 22, 2021 Exhibit 10.1 THIS AGREEMENT, dated July 22, 2021 is made and entered into by and between Edison ICAV, an Irish Collective Investment Asset-management Vehicle, acting for and on behalf of its sub-fund, the Essex Fund, as assignee of Baker Bros. Advisors, LP, a Delaware limited partnership (the ?Buyer?), and Kodiak Sciences Inc., a Delaware corporation (?Kodiak?) together with its Subsidiary Kodiak |
|
| July 23, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 Kodiak Sciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 9, 2021 |
KOD / Kodiak Sciences Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Kodiak Sciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50015M109 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| June 8, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 10, 2021 Registration No. |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 KODIAK SCIENCES INC. |
|
| May 10, 2021 |
Exhibit 99.1 Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA ? May 10, 2021 ? Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the first |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defini |
|
| April 28, 2021 |
Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| March 2, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| March 1, 2021 |
Exhibit 4.7 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made as of March 1, 2021 by and among Kodiak Sciences Inc., a Delaware corporation (the ?Company?), and the persons listed on the attached Schedule A who are signatories to this Agreement (each, an ?Investor,? and collectively, the ?Investors?). Unless otherwise defined herein, capitalized terms used |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 KODIAK SCIENCES INC. |
|
| March 1, 2021 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights Palo Alto, CA — March 1, 2021 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resul |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 16, 2021 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Kodiak Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 50015M109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Ru |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kodiak Sciences Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 2, 2021 |
us50015m1099020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) KODIAK SCIENCES INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 50015M109 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 24, 2020 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| November 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 18, 2020 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION KODIAK SCIENCES INC. 5,193,237 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement November 17, 2020 J.P. MORGAN SECURITIES LLC MORGAN STANLEY & CO. LLC JEFFERIES LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Mor |
|
| November 18, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250109 CALCULATION OF REGISTRATION FEE Title Of Each Class Of Securities To Be Registered Amount To Be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount Of Registration Fee Common Stock, $0.0001 par value 5,972,222(1) $108.00 $644,999,976 $70,370(2) (1) Includes 778,985 |
|
| November 16, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 16, 2020. |
|
| November 16, 2020 |
Form of Indenture, between the Company and one or more trustees to be named. EX-4.5 Exhibit 4.5 KODIAK SCIENCES INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| November 16, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing unde |
|
| November 16, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 KODIAK SCIENCES INC., AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exi |
|
| November 16, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exis |
|
| November 16, 2020 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250109 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| November 9, 2020 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA — November 9, 2020 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the t |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 KODIAK SCIENCES INC. |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| September 8, 2020 |
KOD / Kodiak Sciences Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2020 KODIAK SCIENCES INC. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 KODIAK SCIENCES INC. |
|
| August 10, 2020 |
Exhibit 99.1 Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA — August 10, 2020 – Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the s |
|
| August 10, 2020 |
Building 4 Exhibit 10.2 SUBLEASE BY AND BETWEEN 1050 Page Mill Road Property, LLC, a Delaware limited liability company as Landlord and Kodiak Sciences Inc., a Delaware corporation as Tenant June 19, 2020 Building 4 Table of Contents Page ARTICLE 1 REFERENCE 1 1.1 References 1 ARTICLE 2 LEASED PREMISES, TERM AND POSSESSION 6 2.1 Demise Of Leased Premises 6 2.2 Right To Use Common Areas 6 2.3 Lease |
|
| August 10, 2020 |
Building 3 Exhibit 10.1 SUBLEASE BY AND BETWEEN 1050 Page Mill Road Property, LLC, a Delaware limited liability company as Landlord and Kodiak Sciences Inc., a Delaware corporation as Tenant June 19, 2020 Building 3 Table of Contents Page Article 1 REFERENCE1 1.1 References1 Article 2 LEASED PREMISES, TERM AND POSSESSION6 2.1 Demise Of Leased Premises6 2.2 Right To Use Common Areas6 2.3 Lease Comm |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| June 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 9, 2020 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 11, 2020 |
Exhibit 99.1 Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA — May 11, 2020 – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2 |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defini |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 16, 2020 |
KOD / Kodiak Sciences Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| March 16, 2020 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., March 16, 2020 /PRNewswire/ - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for th |
|
| March 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 16, 2020 |
Exhibit 4.6 DESCRIPTION OF COMMON STOCK Kodiak Sciences Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following summary of the terms of our common stock is based upon our amended and restated certificate of incorporation (our “certificate of incorporat |
|
| March 10, 2020 |
KOD / Kodiak Sciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) February 29, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| February 26, 2020 |
KOD / Kodiak Sciences Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 14, 2020 |
KOD / Kodiak Sciences Inc. / Perlroth Victor - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2020 |
KOD / Kodiak Sciences Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Kodiak Sciences Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 50015M109 (CUSIP NUMBER) December 31, 2019 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| February 14, 2020 |
KOD / Kodiak Sciences Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kodiak Sciences Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| January 28, 2020 |
KOD / Kodiak Sciences Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kodiak Sciences Inc (Name of Issuer) Common Stock (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 17, 2020 |
KOD / Kodiak Sciences Inc. / Moskovitz Dustin A. - KODIAK SCIENCES SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kodiak Sciences Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50015M109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 6, 2019 |
Exhibit 99.2 [Kodiak Letterhead] December 1, 2019 Baker Bros. Advisors, LP 860 Washington Street, 3rd Floor New York, New York 10014 Re: Issuance of Common Stock Ladies and Gentlemen: This letter will confirm our agreement that, subject in all cases to compliance with applicable securities laws and regulations, and subject to and in consideration of the funding agreed to be provided by Baker Bros. |
|
| December 6, 2019 |
KOD / Kodiak Sciences Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 4, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 4, 2019 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-234443 Prospectus supplement (To prospectus dated November 14, 2019) 6,000,000 Shares Common stock We are offering 6,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “KOD.” On December 3, 2019, the last reported sale price for our common stock on The Nasdaq Globa |
|
| December 4, 2019 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION KODIAK SCIENCES INC. 6,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement December 3, 2019 J.P. MORGAN SECURITIES LLC GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Goldman Sachs & Co. LLC 200 |
|
| December 3, 2019 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-234443 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| December 2, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 2, 2019 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION FUNDING AGREEMENT BY AND BETWEEN KODIAK SCIENCES INC., KODIAK SCIENCES GMBH AND BAKER BROS. ADVISORS, LP DATED AS OF DECEMBER 1, 2019 Table of Contents Page ARTICLE 1 PURCHASE, SALE AND ASSIGNMENT OF THE ACQUIRED INTANGIBLES 1 Section 1.1 Purchase, Sale and Assignment 1 Section 1.2 Purchase Price 1 Section 1.3 No Assumed Obligations, Etc. 1 Section 1.4 Buy-Ba |
|
| November 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2019 |
KOD / Kodiak Sciences Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIA |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2019 |
Three Months Ended September 30, Exhibit 99.1 Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third quarter |
|
| November 12, 2019 |
November 12, 2019 John A. Borgeson Chief Financial Officer Kodiak Sciences Inc. 2631 Hanover Street Palo Alto, California 94304 Re: Kodiak Sciences Inc. Registration Statement on Form S-3 Filed November 1, 2019 File No. 333-234443 Dear Mr. Borgeson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests |
|
| November 12, 2019 |
KOD / Kodiak Sciences Inc. CORRESP - - CORRESP KODIAK SCIENCES INC. 2631 Hanover Street Palo Alto, California 94304 (650) 281-0850 November 12, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Gregory Dundas Re: Kodiak Sciences Inc. Registration Statement on Form S-3 File No. 333-234443 Acceleration Request Requested Date: Thursday, November 14, 2019 |
|
| November 12, 2019 |
KOD / Kodiak Sciences Inc. TEXT-EXTRACT - - November 12, 2019 John A. Borgeson Chief Financial Officer Kodiak Sciences Inc. 2631 Hanover Street Palo Alto, California 94304 Re: Kodiak Sciences Inc. Registration Statement on Form S-3 Filed November 1, 2019 File No. 333-234443 Dear Mr. Borgeson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests |
|
| November 1, 2019 |
KOD / Kodiak Sciences Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2019. |
|
| November 1, 2019 |
Form of Indenture, between the Company and one or more trustees to be named. EX-4.5 Exhibit 4.5 KODIAK SCIENCES INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| November 1, 2019 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing unde |
|
| November 1, 2019 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 KODIAK SCIENCES INC., AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exi |
|
| November 1, 2019 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 KODIAK SCIENCES INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KODIAK SCIENCES INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between KODIAK SCIENCES INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exis |
|
| October 15, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 15, 2019 |
Press Release dated October 11, 2019 Exhibit 99.1 Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day - Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eye |
|
| October 10, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 12, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2019 |
Exhibit 99.1 Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights Palo Alto, CA – August 14, 2019 – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 3 |
|
| August 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 14, 2019 |
KOD / Kodiak Sciences Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCI |
|
| July 29, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 29, 2019 |
Press Release issued by Kodiak Sciences Inc. dated July 27, 2019 Exhibit 99.1 Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting - Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic in |
|
| June 5, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2019 KODIAK SCIENCES INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38682 27-0476525 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 KODIAK SCIENCES INC. |
|
| May 15, 2019 |
Exhibit 99.1 Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., May 15, 2019 /PRNewswire/ – Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter e |
|
| May 15, 2019 |
KOD / Kodiak Sciences Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38682 KODIAK SCIENCES INC. |
|
| May 15, 2019 |
KOD / Kodiak Sciences Inc. S-8 S-8 As filed with the Securities and Exchange Commission on May 15, 2019 Registration No. |
|
| April 24, 2019 |
KOD / Kodiak Sciences Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defini |
|
| April 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defini |
|
| March 28, 2019 |
Three Months Ended December 31, Exhibit 99.1 Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights PALO ALTO, Calif., March 28, 2019 /PRNewswire/ - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the four |
|
| March 28, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 KODIAK SCIENCES INC. |
